OBJECTIVE: To develop and validate a shortened version of the Valued Life Activities disability and accommodations scale (VLA) for individuals with rheumatoid arthritis (RA). METHODS: To shorten the existing VLA measure, item response theory analyses were conducted using data from 449 patients with RA. Next, the resulting 14-item shortened version of the VLA scale (S-VLA) was evaluated by structured interviews among 20 RA patients. Lastly, the S-VLA was administered to 150 RA patients along with other measures, including the Health Assessment Questionnaire (HAQ) and Short Form 36 (SF-36). A random sample of 50 patients completed the S-VLA 2 weeks later to assess reliability. Item statistics were calculated to evaluate correlations between individual items and the S-VLA total score. Correlations between the S-VLA and other measures were used to evaluate validity. RESULTS: Test-retest reliability was 0.91, while Cronbach's alpha for the S-VLA was 0.95. None of the 14 items was associated with improved alpha coefficients when omitted. All of the items were strongly correlated with the S-VLA total score. S-VLA scores were highly positively correlated with the HAQ (r = 0.81, P ≤ 0.001), patient-reported disease activity (r = 0.71, P ≤ 0.001), satisfaction with abilities (r = 0.82, P ≤ 0.001), and number of days with activity limitations (r = 0.65, P ≤ 0.001). In addition, as hypothesized, the S-VLA was inversely correlated with the SF-36 physical component summary score (r = -0.78, P ≤ 0.001) and the physical functioning (r = -0.80, P ≤ 0.001), role physical (r = -0.67, P ≤ 0.001), and social functioning (r = -0.72, P ≤ 0.001) subscales. CONCLUSION: The S-VLA is a short, valid, and reliable instrument that may prove useful for monitoring disability among individuals with RA.
OBJECTIVE: To develop and validate a shortened version of the Valued Life Activities disability and accommodations scale (VLA) for individuals with rheumatoid arthritis (RA). METHODS: To shorten the existing VLA measure, item response theory analyses were conducted using data from 449 patients with RA. Next, the resulting 14-item shortened version of the VLA scale (S-VLA) was evaluated by structured interviews among 20 RApatients. Lastly, the S-VLA was administered to 150 RApatients along with other measures, including the Health Assessment Questionnaire (HAQ) and Short Form 36 (SF-36). A random sample of 50 patients completed the S-VLA 2 weeks later to assess reliability. Item statistics were calculated to evaluate correlations between individual items and the S-VLA total score. Correlations between the S-VLA and other measures were used to evaluate validity. RESULTS: Test-retest reliability was 0.91, while Cronbach's alpha for the S-VLA was 0.95. None of the 14 items was associated with improved alpha coefficients when omitted. All of the items were strongly correlated with the S-VLA total score. S-VLA scores were highly positively correlated with the HAQ (r = 0.81, P ≤ 0.001), patient-reported disease activity (r = 0.71, P ≤ 0.001), satisfaction with abilities (r = 0.82, P ≤ 0.001), and number of days with activity limitations (r = 0.65, P ≤ 0.001). In addition, as hypothesized, the S-VLA was inversely correlated with the SF-36 physical component summary score (r = -0.78, P ≤ 0.001) and the physical functioning (r = -0.80, P ≤ 0.001), role physical (r = -0.67, P ≤ 0.001), and social functioning (r = -0.72, P ≤ 0.001) subscales. CONCLUSION: The S-VLA is a short, valid, and reliable instrument that may prove useful for monitoring disability among individuals with RA.
Authors: Jonathan Paul Singer; Paul David Blanc; Y Monica Dean; Steven Hays; Lorriana Leard; Jasleen Kukreja; Jeffrey Golden; Patricia P Katz Journal: Thorax Date: 2013-12-19 Impact factor: 9.139
Authors: James S Andrews; Laura Trupin; Edward H Yelin; Catherine L Hough; Kenneth E Covinsky; Patricia P Katz Journal: Clin Rheumatol Date: 2017-01-23 Impact factor: 2.980
Authors: Jonathan Paul Singer; Joan Chen; Patricia P Katz; Paul David Blanc; Marjorie Kagawa-Singer; Anita L Stewart Journal: Qual Life Res Date: 2014-12-04 Impact factor: 4.147
Authors: Patricia P Katz; Jennifer Barton; Laura Trupin; Gabriela Schmajuk; Jinoos Yazdany; Pedro J Ruiz; Edward Yelin Journal: Arthritis Care Res (Hoboken) Date: 2016-05 Impact factor: 4.794
Authors: James S Andrews; Laura Trupin; Katherine D Wysham; Catherine L Hough; Edward H Yelin; Patricia P Katz Journal: ACR Open Rheumatol Date: 2019-07-28
Authors: Alissa Walsh; Rena Cao; Darren Wong; Ramona Kantschuster; Lawrence Matini; Jean Wilson; Andrey Kormilitzin; Matthew South; Simon Travis; Sarah Bauermeister Journal: BMC Gastroenterol Date: 2021-03-22 Impact factor: 3.067
Authors: Kathryn R Martin; Eva-Maria Bachmair; Lorna Aucott; Emma Dures; Richard Emsley; Stuart R Gray; Sarah Hewlett; Vinod Kumar; Karina Lovell; Gary J Macfarlane; Graeme MacLennan; Paul McNamee; John Norrie; Lorna Paul; Stuart Ralston; Stefan Siebert; Alison Wearden; Peter D White; Neil Basu Journal: BMJ Open Date: 2019-01-30 Impact factor: 2.692
Authors: Patricia Katz; Sofia Pedro; Evo Alemao; Jinoos Yazdany; Maria Dall'Era; Laura Trupin; Stephanie Rush; Kaleb Michaud Journal: ACR Open Rheumatol Date: 2019-12-04